glp-1 receptor agonist kidney outcomes semaglutide flow trial 2024 results With Glucagon-Like Peptide-1 Agonists in Patients With Type 2 Diabetes Kidney and Cardiovascular Outcomes Among
Description
Retrieved from National Library of Medicine
doi: 10.1056/NEJMoa1411892 93 WaddenTAHollanderPKleinSNiswenderKWooVHalePMet al
Available from: [Google Scholar] 50.Finan B, Ma T, Ottaway N, Muller TD, Habegger KM, Heppner KM, et al
Unlike oral semaglutide (which requires taking the pill on an empty stomach with limited water and waiting 30 minutes before eating), orforglipron has no food or water restrictions
Constipation self-care
Noguchi, T
